<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
<item congress="114" measure-type="hr" measure-number="3299" measure-id="id114hr3299" originChamber="HOUSE" orig-publish-date="2015-07-29" update-date="2016-06-21">
<title>Strengthening Public Health Emergency Response Act of 2015</title>
<summary summary-id="id114hr3299v00" currentChamber="HOUSE" update-date="2016-06-21">
<action-date>2015-07-29</action-date>
<action-desc>Introduced in House</action-desc>
<summary-text><![CDATA[<p><b>Strengthening Public Health Emergency Response Act of 2015</b></p> <p>This bill amends the Public Health Service Act to require the program to enhance community and hospital preparedness for public health emergencies to use at least 97% of its funding for awards.</p> <p>The Government Accountability Office must report on programs for public health emergency preparedness.</p> <p>The Department of Health and Human Services (HHS) must ensure procedures are in place to coordinate the ongoing stockpiling of countermeasures (certain medical supplies) by the Biomedical Advanced Research and Development Authority (BARDA) and Centers for Disease Control and Prevention.</p> <p>Procurement of countermeasures using the Biodefense Countermeasures appropriations account no longer requires Presidential approval or an agreement between HHS and the Department of Homeland Security (DHS). </p> <p>BARDA is given direct contracting authority.</p> <p>The annual countermeasures plan developed by the Office of the Assistant Secretary for Preparedness and Response must report on the amount of time between a BARDA request and the award of a contract.</p> This bill amends the Federal Food, Drug, and Cosmetic Act to add diseases and other agents that are determined to be a material threat by DHS to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a listed disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)]]></summary-text>
</summary>
</item>
<dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
<dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
</dublinCore>
</BillSummaries>
